Imagion Biosystems has announced and amendment to the proposed timetable for the Pro-Rata Renounceable Rights Issue as announced on Monday, 28 October 2019.
Read the amended timetable.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer